(Q34124126)

31 July 2017

1 reference

title

Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials (English)

1 reference

31 July 2017

Horning JS

1

1 reference

31 July 2017

publication date

1 October 2000

1 reference

31 July 2017

published in

Seminars in Hematology

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

4 Suppl 7

1 reference

31 July 2017

page(s)

27-33

1 reference

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990057-X

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990057-X

7 January 2021

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990057-X

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990057-X

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990057-X

7 January 2021

10.1016/S0037-1963(00)90057-X

Identifiers

DOI

1 reference

31 July 2017

1 reference